ABERDEEN PROVING GROUND, Md.--(BUSINESS WIRE)-- The Army Contracting Command -Aberdeen Proving Ground (ACC-APG) Contracting Center, Natick Contracting Division, Natick, MA, in support of the Joint Program Executive Office-Chemical and Biological Defense (JPEO CBD), Joint Project Manager - Medical Countermeasure Manufacturing Advanced Development Manufacturing (JPM-MCM ADM), is pleased to announce the issuance of a Request for Proposal (RFP) on the basis of full and open competition on 26 August 2011 for the Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) Capability. The Government intends to award a contract to provide the DoD with an enduring capability and infrastructure to meet DoD requirements/demands for advanced development and manufacturing of Medical Countermeasures (MCMs).
The overall goal for the contractor is to collaborate, and work with Government (to include the Food and Drug Administration), academia, and industry to reduce the overall time and cost associated with the development and manufacturing of Food and Drug Administration (FDA) approved MCMs, and provide the DoD, and by extension the United States Government (USG), the capability for agile and flexible advanced development and manufacturing. The ADM capability shall integrate flexible, modular (single use, disposable), adaptable and scalable processes and equipment that can provide:
- Capability that allows third parties to develop candidates and provide products to the USG by leveraging ADM's core competencies and facilities while ensuring Intellectual Property is protected
- Streamlined advanced development capability that reduces risk (cost and schedule)
- Manufacturing and warm-base capabilities to rapidly respond to CBRN events and emerging and genetically engineered infectious disease outbreaks by producing FDA approvable products or expand (surge) manufacturing of existing FDA approved products without requiring additional regulatory approvals
- Strategies for using the ADM capability to support and facilitate transition of processes, technologies, and individual MCM candidates from Science and Technology efforts and/or novel industry innovations. The type of requirements would include, but not limited to: novel platform/expression systems for MCMs, advancements in regulatory science, and advancements in flexible manufacturing enabling technologies for MCMs.
- Assistance and training for workforce development in the areas of drug development and manufacturing including the use of the ADM capabilities
The MCM ADM capability may be centralized or distributed within the United States and its territories, and may include international participation. The contractor will establish, own and operate the MCM ADM capability within the United States. This project supports only the establishment and commissioning of the MCM ADM capability and the sustainment of the capability to enable the advanced development of vaccines, and/or drugs, and the rapid response to advanced development and manufacturing needs as they arise. All activities related to specific MCM advanced development and manufacturing requirements will be executed as separate contracts with third-party entities that will use this capability as a directed source.
The USG will evaluate proposals in accordance with FAR 15, Contracting by Negotiation, and intends to make a single award to the offer or whose proposal represents Best Value to the USG. The resulting contract will be a ten (10) year contract with a base period of two (2) years and four (4) two-year option periods. Contract type will be Cost Reimbursement. The NAICS code assigned to this acquisition is 325412 with applicable Small business size standard of 750 average number of employees.
The solicitation and associated attachments can be accessed from the Federal Business Opportunities website (www.fbo.gov), the solicitation link on this page, or can be downloaded from the Natick Contracting Division website link below.
The announcement number W911QY-11-R-0023 will be the controlling document for preparation and submission of proposals. All responsible sources may submit a proposal to be considered by this agency. The USG is in no way liable to pay for or reimburse companies or entities that respond to this RFP.
No hard copy of this solicitation will be issued. Amendments, if any, will be posted at the same location as the RFP. It is the responsibility of those respondents to obtain all amendments and applicable documents. The closing date for submission of proposals is stated in the solicitation. Award of the proposed contract is subject to the availability of funds. The Government plans to conduct a pre-proposal conference via Webinar with interested parties on 12 September 2011 from 1:00 PM to 4:00 PM. Questions received prior to close of business on 7 September 2011 will be addressed during the conference. Additional details regarding this Webinar will be forthcoming.
Questions regarding this solicitation will only be accepted in writing via e-mail to [email protected] with a courtesy copy to [email protected]
Link to solicitation:
https://acquisition.army.mil/asfi/solicitation_view.cfm?psolicitationnbr=W911QY11R0023
ACC-APG Natick Contracting Division
CONTACT:
Joint Program Executive Office for Chemical and Biological Defense
Jean Greenwood
[email protected]
or
Peter Wallace
[email protected]
KEYWORDS: United States North America District of Columbia
INDUSTRY KEYWORDS: Technology Security Health Alternative Medicine Biotechnology Hospitals Infectious Diseases Public Policy/Government Medical Devices Homeland Security Pharmaceutical Manufacturing Public Policy White House/Federal Government Chemicals/Plastics Defense Contracts Research Medical Supplies Science
MEDIA: